Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Charles River Laboratories International, Inc. has 47.73M shares outstanding.

As of June 30, 2026, Charles River Laboratories International, Inc. maintains a current ratio of 1.35, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 104.82, indicating elevated leverage, while an interest coverage ratio of 3.65 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Charles River Laboratories International, Inc. posted a negative return on equity (ROE) of -7.70, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.16, reflecting losses generated across the asset base. The company generates approximately 176,783.50 in revenue per employee across its workforce of 19,800.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.60 indicates how many times Charles River Laboratories International, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Charles River Laboratories International, Inc. recorded 46.06M in income tax expense. The company reported a pretax loss of -160.77M and -208.72M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, Charles River Laboratories International, Inc. generated 3.50B in revenue and converted that into -208.72M in net income, yielding earnings per share of -4.23. EBITDA reached 339.64M, while operating income came in at 407.99M.

As of June 30, 2026, Charles River Laboratories International, Inc. holds 168.08M in cash and equivalents against 2.65B in total debt, resulting in a net debt position of 2.13B. Total book value stands at 2.49B, with working capital of 345.18M providing operational flexibility.

Charles River Laboratories International, Inc. produced 509.55M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Charles River Laboratories International, Inc. posted a gross margin of 32.67, reflecting its pricing power and cost economics. The operating margin of 11.66 and net profit margin of -5.96 provide insight into operational efficiency.